先进的纳米输送系统在H. 杆菌根除:向,疗效和临床翻译
Tehsin Ullah Khan1, Mohamed Sharaf1,2, Sohaib Khan3
1Department of Biochemistry and Molecular Biology, College of Marine Life Sciences, Ocean University of China, Qingdao, PR China.
Expert opinion on drug delivery
|October 3, 2025
概括
纳米颗粒为抗击Helicobacter pylori感染提供了新的方法,克服了抗生素耐药性. 这些先进的系统可以改善药物输送,有效地向细菌并减少副作用.
科学领域:
- 纳米医学是一种纳米医学.
- 提供抗微生物药物的药物.
- 胃肠病学 胃肠病学
背景情况:
- Helicobacter pylori 中抗生素耐药性的增加需要新的治疗方法.
- 传统的治疗方法面临的局限性包括生物可用性差以及肠道微生物群的破坏.
研究的目的:
- 审查基于纳米粒子 (NP) 的药物递送系统对H. pylori的最新进展.
- 突出NP相对于传统抗生素输送方法的优势.
主要方法:
- 对金属,聚合物,基于脂质和仿生纳米载体的检查.
- 在H. pylori治疗中分析NP设计,功能和性能.
- 审查表明药物生物可用性和生物膜透率提高的研究.
主要成果:
- 基于脂质的NP显示了hesperidin和clarithromycin的协同交付.
- 聚合NPs在胃粘液中实现了>99%的生物膜消除.
- 纳米平台展示了精确的胃粘膜向和受控释放.
结论:
- 基于NP的系统通过改善药物输送和最大限度地减少全身暴露来增强对H. pylori的抗菌疗效.
- 进一步的临床验证对于将NP技术转化为标准化的治疗方法至关重要.
- 这些创新有望减少H. pylori相关疾病的全球负担.
相关概念视频
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
1.1K
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
1.1K
Peptic Ulcer Disease IV: Management
430
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
430
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
536
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
536
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
845
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
845


